[stock_market_widget type=”card” template=”basic2″ assets=”GLASF” realtime=”true” api=”yahoo-finance”]
A California cannabis company that grows some of the state’s largest volumes of cannabis flower took a significant structural step this week, one that reflects just how quickly the landscape for U.S. cannabis investing is shifting.
Glass House Brands Inc. (OTCQX: GLASF) announced that it has applied to list its subordinate voting shares on the New York Stock Exchange. To get there, the company executed what it calls a deconsolidation transaction, essentially separating two distinct sides of its business that had previously operated under the same corporate roof.
The company was founded in 2015 and has grown into one of California’s largest vertically integrated cannabis operations, meaning it handles everything from cultivation to retail under one umbrella. It operates what is reported to be the largest greenhouse cannabis cultivation facility in the state, a sprawling SoCal Farm in Camarillo spanning over 5.5 million square feet. Its brand portfolio includes Glass House Farms, PLUS Products, Allswell, and Mama Sue Wellness.
To understand why the company restructured, it helps to understand the difference between two types of cannabis operations it runs. Dual-use cannabis, sometimes called adult-use or recreational cannabis, is sold to any adult who walks into a dispensary. Medical cannabis, by contrast, is dispensed to patients who have received authorization from a healthcare provider. Until recently, both categories were treated identically under federal law, classified as Schedule I controlled substances with no accepted medical use. That classification made it essentially impossible for U.S. cannabis companies to list on major domestic stock exchanges like the NYSE.
That changed in April 2026. The Department of Justice issued an order immediately placing cannabis “subject to a state medical marijuana license” in Schedule III of the Controlled Substances Act, removing state-licensed medical cannabis operators from the deduction disallowance imposed by Section 280E of the Internal Revenue Code. That matters enormously from a financial standpoint. Under the prior Schedule I classification, cannabis companies were taxed on gross profit rather than net income, with effective tax rates that routinely ran well above 50%. Medical cannabis operators no longer face that burden.
The NYSE’s current rules, however, still do not permit companies to consolidate the financial results of adult-use cannabis operations. That is precisely why Glass House separated the two. Under the deconsolidation transaction, its adult-use retail business was transferred into a separate entity called Glass House Retail, LLC, now controlled by a third-party investor. Glass House retained non-voting, non-participating units in that entity, meaning it holds a financial interest but no longer controls or consolidates the adult-use side on its books. The medical cannabis business remains within the publicly listed parent company, which is the entity applying to the NYSE.
This structure is not entirely new to the cannabis sector. Trulieve Cannabis Corp. (NYSE: TRLV) became the first U.S. plant-touching marijuana operator to list on the NYSE, effective earlier this month on the 10th, after executing a corporate restructuring to completely deconsolidate its adult-use operations. Glass House is now following a broadly similar approach.
The practical significance of landing on the NYSE goes well beyond a ticker symbol change. Today, Glass House trades on the OTCQX, an over-the-counter market that, while legitimate, carries limitations. Many institutional money managers, including mutual funds, simply cannot own stocks that trade on the over-the-counter marketplace or on foreign exchanges because of their investment mandates. Moving to the NYSE removes that barrier, opening the company’s shares to a broader pool of institutional capital. Analysts have noted that rescheduling and exchange listing milestones could boost earnings, cash flow, capital access, banking services, and institutional participation across the sector.
Glass House has also been expanding aggressively. In April 2026, it announced a joint venture with Vireo Growth to build one of California’s largest cannabis retail platforms, with each company contributing its California dispensary operations to the joint entity in exchange for a 50% ownership interest. The company has also been accelerating greenhouse production and exploring markets beyond California.
It is worth noting that Glass House’s NYSE application is just that, an application. Approval is not guaranteed and the timeline is not yet confirmed. The company’s non-voting units in Glass House Retail can only convert back into voting units after the NYSE formally permits companies to consolidate adult-use cannabis financials, a threshold that has not yet been crossed.
The broader regulatory environment, including a DEA administrative hearing on full rescheduling set to begin later this month on the 29th, will likely shape how quickly that threshold is reached. If the broader rescheduling is finalized, it would extend Schedule III status to the adult-use cannabis market, with significant implications for taxation, banking, and capital market access across the industry. For Glass House, the corporate restructuring it completed this week is the starting point of what could be a longer journey toward a fully consolidated major exchange listing.
